A new epilepsy therapy is to be made available in Europe following its approval by the European Commission.Brivaracetam, which will be sold under the brand name Briviact, has been given the green light for sale as an adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation, in adults and adolescents from 16 years of age with epilepsy.Developed by UCB, the new antiepileptic drug (AED) is notable for being initiated without titration, meaning patients can receive a therapeutic dose of the drug from the first day of treatment.The therapy has been approved based on positive data from three pivotal phase III studies, in which it demonstrated statistically significant reductions in partial-onset seizure frequency compared to placebo.It was shown that 34.2% of patients receiving a 50 mg daily dose experienced a 50% or greater reduction in partial-onset seizure frequency, and this rose to 39.5% for a 100 mg dose and 37.8% for a 200 mg dose.Overall, the clinical development programme for the drug has involved more than 3,000 people, with certain individuals accruing over eight years of experience with the therapy.Dr Manuel Toledo, Consultant Neurologist and Epileptologist at the Vall d’Hebron Hospital in Barcelona, who participated in the clinical trials of the new drug, said: “There is an unmet need for epilepsy medicines that effectively control seizures and are also well tolerated by patients.”A new treatment such as Briviact that enables patients to receive a therapeutic dose from the very first day without titration represents a big step forward to further helping people with epilepsy.”Currently, it is estimated that around one-third of the 65 million people worldwide affected by epilepsy are resistant to the treatments that are currently available, making the availability of new therapy options an important priority in drug development.Posted by Bob JonesClick here for more articles about anti-epileptic drugs and pregnancy risks.